ResMed | RMD - Cost Of Sales


ResMed reported $612.93M in Cost of Sales for its fiscal quarter ending in June of 2026.





Cost Of Sales Change Date
Ansell USD 605.3M 351.2M Dec/2025
Artivion USD 42.85M 3.86M Dec/2025
AtriCure USD 34.98M 3.04M Jun/2026
Baxter International USD 1.93B 118M Jun/2026
Cochlear AUD 319.2M 160.35M Dec/2025
Cooper Companies USD 401.3M 7.5M Jun/2026
CSL USD 3.87B 2.08B Dec/2025
Dexcom USD 478.4M 36.8M Jun/2026
Edwards Lifesciences USD 392.4M 29.8M Jun/2026
Fisher Paykel Healthcare NZD 435.5M 32.7M Jun/2026
Globus Medical USD 271M 7.41M Jun/2026
Haemonetics USD 136.58M 11.56M Jun/2026
Idexx Laboratories USD 437.5M 19.42M Jun/2026
Inogen USD 39.59M 1.27M Sep/2024
Insulet USD 239.1M 6.4M Jun/2026
Integra LifeSciences USD 188.86M 10.15M Jun/2026
Intuitive Surgical USD 931.9M 8.4M Jun/2026
Medtronic USD 3.83B 26M Jun/2026
Philips EUR 2.21B 70M Jun/2026
Ramsay Health Care AUD 3.05B 78.7M Dec/2025
ResMed USD 612.93M 61.26M Jun/2026
Sigma Healthcare AUD 1.55B 165.16M Dec/2024
Sonic Healthcare AUD 751.66M 801.13M Dec/2024
Steris USD 808.6M 82.7M Jun/2026
Teleflex USD 238.62M 2.21M Jun/2026
Thermo Fisher Scientific USD 7.54B 577M Jun/2026